Top

Journal of Mammary Gland Biology and Neoplasia

Published in:

01-03-2009

ABC Transporters, Drug Resistance, and Cancer Stem Cells

Author: Michael Dean

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 1/2009

Abstract

The protection of the body’s stem cells from damage or death due to toxins is a critical function of an organism, as the stem cells need to remain intact for the entire life of the organism. One of the principal mechanisms for protecting stem cells is through the expression of multifunctional efflux transporters from the ATP-binding cassette (ABC) gene family. These same transporters have been known for over 25 years to also play a role in multidrug resistance of tumor cells. An exciting outcome of the concept of the cancer stem cell is that the tumor initiating cell may be innately resistant to many standard therapies. This provides one mechanism in which cancer stem cells could survive cytotoxic or targeted therapies and lead to tumor regrowth or relapse. Gaining a better insight into the mechanisms of stem cell resistance to chemotherapy might therefore lead to new therapeutic targets and better anti-cancer strategies.

Higgins CF. ABC transporters: From micro-organisms to man. Annu Rev Cell Biol. 1992;8:67–113. doi:10.1146/annurev.cb.08.110192.000435.PubMedCrossRef

Childs S, Ling V. The MDR superfamily of genes and its biological implications. Important Adv Oncol. 1994;1994:21–36.

Dean M, Allikmets R. Evolution of ATP-binding cassette transporter genes. Curr Opin Genet Dev. 1995;5:779–85. doi:10.1016/0959–437X(95)80011-S.PubMedCrossRef

Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11(7):1156–66. doi:10.1101/gr.GR-1649R.PubMedCrossRef

Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature. 1990;346(6282):362–5. doi:10.1038/346362a0.PubMedCrossRef

Locher KP. Structure and mechanism of ABC transporters. Curr Opin Struct Biol. 2004;14(4):31. doi:10.1016/j.sbi.2004.06.005.CrossRef

Locher KP, Lee AT, Rees DC. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science. 2002;296(5570):1091–8. doi:10.1126/science.1071142.PubMedCrossRef

Kadaba NS, Kaiser JT, Johnson E, Lee A, Rees DC. The high-affinity E. coli methionine ABC transporter: structure and allosteric regulation. Science. 2008;321(5886):250–3. doi:10.1126/science.1157987.PubMedCrossRef

Hvorup RN, Goetz BA, Niederer M, Hollenstein K, Perozo E, Locher KP. Asymmetry in the structure of the ABC transporter-binding protein complex BtuCD-BtuF. Science. 2007;317(5843):1387–90. doi:10.1126/science.1145950.PubMedCrossRef

10.

Annilo T, Chen ZQ, Shulenin S, Costantino J, Thomas L, Lou H, et al. Evolution of the vertebrate ABC gene family: analysis of gene birth and death. Genomics. 2006;88(1):1–11. doi:10.1016/j.ygeno.2006.03.001.PubMedCrossRef

11.

Martinoia E, Klein M, Geisler M, Bovet L, Forestier C, Kolukisaoglu U, et al. Multifunctionality of plant ABC transporters–more than just detoxifiers. Planta. 2002;214(3):345–55. doi:10.1007/s004250100661.PubMedCrossRef

12.

Dean M, Annilo T. Evolution of the ATP-Binding Cassette (ABC) Transporter Superfamily in Vertebrates. Ann Rev Hum Genet Genom. 2005;6:123–42. doi:10.1146/annurev.genom.6.080604.162122.CrossRef

13.

Gottesman MM, Ludwig J, Xia D, Szakacs G. Defeating drug resistance in cancer. Discov Med. 2006;6(31):18–23.PubMed

14.

Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58. doi:10.1038/nrc706.PubMedCrossRef

15.

Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316(6031):820–3. doi:10.1038/316820a0.PubMedCrossRef

16.

Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47(3):381–9. doi:10.1016/0092-8674(86)90595-7.PubMedCrossRef

17.

Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 1985;316(6031):817–9. doi:10.1038/316817a0.PubMedCrossRef

18.

Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–84. doi:10.1038/nrc1590.PubMedCrossRef

19.

Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650–4. doi:10.1126/science.1360704.PubMedCrossRef

20.

Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res. 2002;8(1):22–8.PubMed

21.

Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998;58:5337–9.PubMed

22.

Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 1999;59:8–13.PubMed

23.

Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95(26):15665–70. doi:10.1073/pnas.95.26.15665.PubMedCrossRef

24.

Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3–29. doi:10.1016/S0169-409X(02)00169-2.PubMedCrossRef

25.

Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002;99(2):507–12. doi:10.1182/blood.V99.2.507.PubMedCrossRef

26.

Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A. 2002;99(19):12339–44. doi:10.1073/pnas.192276999.PubMedCrossRef

27.

Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A. 2002;99(24):15649–54. doi:10.1073/pnas.202607599.PubMedCrossRef

28.

Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491–502. doi:10.1016/0092-8674(94)90212-7.PubMedCrossRef

29.

Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183(4):1797–806. doi:10.1084/jem.183.4.1797.PubMedCrossRef

30.

Summer R, Kotton DN, Sun X, Ma B, Fitzsimmons K, Fine A. Side population cells and Bcrp1 expression in lung. Am J Physiol Lung Cell Mol Physiol. 2003;285(1):L97–104.PubMed

31.

Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco MM, et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 2003;5(1):R1–8. doi:10.1186/bcr563.PubMedCrossRef

32.

Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7(9):1028–34. doi:10.1038/nm0901-1028.PubMedCrossRef

33.

Lassalle B, Bastos H, Louis JP, Riou L, Testart J, Dutrillaux B, et al. ‘Side Population’ cells in adult mouse testis express Bcrp1 gene and are enriched in spermatogonia and germinal stem cells. Development. 2004;131(2):479–87. doi:10.1242/dev.00918.PubMedCrossRef

34.

Asakura A, Rudnicki MA. Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp Hematol. 2002;30(11):1339–45. doi:10.1016/S0301-472X(02)00954-2.PubMedCrossRef

35.

Martin CM, Meeson AP, Robertson SM, Hawke TJ, Richardson JA, Bates S, et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol. 2004;265(1):262–75. doi:10.1016/j.ydbio.2003.09.028.PubMedCrossRef

36.

Lechner A, Leech CA, Abraham EJ, Nolan AL, Habener JF. Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. Biochem Biophys Res Commun. 2002;293(2):670–4. doi:10.1016/S0006-291X(02)00275-9.PubMedCrossRef

37.

Terunuma A, Jackson KL, Kapoor V, Telford WG, Vogel JC. Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells. J Invest Dermatol. 2003;121(5):1095–103. doi:10.1046/j.1523-1747.2003.12531.x.PubMedCrossRef

38.

Zhou S, Zong Y, Lu T, Sorrentino BP. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. Biotechniques. 2003;35(6):1248–52.PubMed

39.

Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 2004;64(4):1247–51. doi:10.1158/0008-5472.CAN-03-3583.PubMedCrossRef

40.

van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, et al. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol. 2007;27(4):1247–53. doi:10.1128/MCB.01621-06.PubMedCrossRef

41.

Olsen HG, Nilsen H, Hayes B, Berg PR, Svendsen M, Lien S, et al. Genetic support for a quantitative trait nucleotide in the ABCG2 gene affecting milk composition of dairy cattle. BMC Genet. 2007;8:32. doi:10.1186/1471-2156-8-32.PubMedCrossRef

42.

Cohen-Zinder M, Seroussi E, Larkin DM, Loor JJ, Everts-van der Wind A, Lee JH, et al. Identification of a missense mutation in the bovine ABCG2 gene with a major effect on the QTL on chromosome 6 affecting milk yield and composition in Holstein cattle. Genome Res. 2005;15(7):936–44. doi:10.1101/gr.3806705.PubMedCrossRef

43.

Farke C, Meyer HH, Bruckmaier RM, Albrecht C. Differential expression of ABC transporters and their regulatory genes during lactation and dry period in bovine mammary tissue. J Dairy Res. 2008;75(4):406–14. doi:10.1017/S002202990800335X.PubMedCrossRef

44.

Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, et al. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res. 2008;68(12):4910–8. doi:10.1158/0008-5472.CAN-08–0303.PubMedCrossRef

45.

Park BH, Davidson NE. PI3 kinase activation and response to Trastuzumab Therapy: what’s neu with herceptin resistance? Cancer Cell. 2007;12(4):297–9. doi:10.1016/j.ccr.2007.10.004.PubMedCrossRef

46.

Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27(47):6120–30. doi:10.1038/onc.2008.207.PubMedCrossRef

47.

Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS. Cancer stem cells in breast: current opinion and future challenges. Pathobiology. 2008;75(2):75–84. doi:10.1159/000123845.PubMedCrossRef

48.

Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol. 2007;176(1):19–26. doi:10.1083/jcb.200604065.PubMedCrossRef

49.

Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004;64(7):2333–7. doi:10.1158/0008-5472.CAN-03-3344.PubMedCrossRef

50.

Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004;65(6):1485–95. doi:10.1124/mol.65.6.1485.PubMedCrossRef

51.

Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004;104(9):2940–2. doi:10.1182/blood-2004-04-1398.PubMedCrossRef

52.

Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell. 2008;14(3):238–49. doi:10.1016/j.ccr.2008.08.003.PubMedCrossRef

53.

Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004;101(39):14228–33. doi:10.1073/pnas.0400067101.PubMedCrossRef

54.

Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000;60(1):47–50.PubMed

55.

Tarasova NI, Seth R, Tarasov SG, Kosakowska-Cholody T, Hrycyna CA, Gottesman MM, et al. Transmembrane inhibitors of P-glycoprotein, an ABC transporter. J Med Chem. 2005;48(11):3768–75. doi:10.1021/jm049065t.PubMedCrossRef

56.

Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 2004;64(9):3296–301. doi:10.1158/0008-5472.CAN-03-2033.PubMedCrossRef

57.

Dean M. Towards a unified model of tumor suppression: lessons learned from the human patched gene. Biochim Biophys Acta. 1997;1332:M43–52.PubMed

58.

Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–51. doi:10.1016/S0092-8674(00)81268-4.PubMedCrossRef

59.

Lee LM, Seftor EA, Bonde G, Cornell RA, Hendrix MJ. The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dyn. 2005;233(4):1560–70. doi:10.1002/dvdy.20471.PubMedCrossRef

Title: ABC Transporters, Drug Resistance, and Cancer Stem Cells
Author: Michael Dean
Publication date: 01-03-2009
Publisher: Springer US
Published in: Journal of Mammary Gland Biology and Neoplasia / Issue 1/2009
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-009-9109-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition Against Cancer Therapies

Hormone-Induced Protection Against Breast Cancer

ER Re-expression and Re-sensitization to Endocrine Therapies in ER-negative Breast Cancers

Stemming Resistance to HER-2 Targeted Therapy

Tumor-Initiating Cells and Treatment Resistance: How Goes the War?

Radiation Resistance of Breast Cancer Stem Cells: Understanding the Clinical Framework

Keynote webinar | Spotlight on antibody–drug conjugates in cancer